Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | MRGPRX1 | Q96LB2 | 3/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12051534 | 0.87 | PDPK1 (0.41) | PDPK1HSD17B10MAPTALDH1A1MEN1 | |
| SCHEMBL179607 | 0.83 | PDPK1 (0.38) | PDPK1HSD17B10MAPTALDH1A1MEN1 | |
| SCHEMBL179602 | 0.83 | LIMK1 (0.38) | PDPK1HSD17B10MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL16399428 | 0.83 | PDPK1 (0.38) | PDPK1HSD17B10MAPTALDH1A1MEN1 | |
| SCHEMBL3921763 | 0.83 | ALDH1A1 (0.39) | PDPK1HSD17B10MAPTALDH1A1MEN1 | |
| SCHEMBL23717803 | 0.83 | PDPK1 (0.38) | PDPK1HSD17B10MAPTALDH1A1MEN1 | |
| SCHEMBL25466893 | 0.79 | PDPK1 (0.36) | PDPK1HSD17B10MAPTALDH1A1MEN1 | |
| SCHEMBL23341813 | 0.79 | PDPK1 (0.36) | PDPK1HSD17B10MAPTALDH1A1MEN1 | |
| SCHEMBL12261899 | 0.79 | YTHDC1 (0.39) | PDPK1HSD17B10MAPTALDH1A1HPGD | |
| SCHEMBL23830360 | 0.79 | HSD17B10 (0.45) | PDPK1HSD17B10MAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220247-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | KSQ Therapeutics, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230203055-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF IN MEDICINE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203046-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230203055-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF IN MEDICINE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20210115049-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2021-04-22 | — | — | US | disclosed |
| EP-3300500-B9 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3541792-B1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3541810-B1 | TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3541805-B1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-20160340336-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2016-11-24 | — | — | US | disclosed |
| US-8076364-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | NAKAMURA YOSHINORI | 2011-04-21 | — | — | US | disclosed |
| US-7906517-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-03-15 | — | — | US | disclosed |
| US-7906517-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090029994-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090029994-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
| WO-2007088996-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| US-20040116480-A1 | Oxime ether compound and agricultural or horticultural bactericide | NIPPON SODA CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1362850-A1 | OXIME ETHER COMPOUND AND AGRICULTURAL OR HORTICULTURAL BACTERICIDE | NIPPON SODA CO., LTD. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | CETP, MTTP, APOB | PDPK1 4179/4885HSD17B10 406/4885MAPT 2667/4885 |
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | USP1, UPP1, USP2 | PDPK1 2108/4885HSD17B10 4263/4885MAPT 3331/4885 |
| US-20210115049-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, UPP1, USP2 | PDPK1 2108/4885HSD17B10 4263/4885MAPT 3331/4885 |
| US-20230203055-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF IN MEDICINE | VIP, CYP11B2, CYP11B1 | PDPK1 1331/4885HSD17B10 640/4885MAPT 4055/4885 |
| US-20230203046-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, UPP1, USP2 | PDPK1 2108/4885HSD17B10 4263/4885MAPT 3331/4885 |
| US-20090029994-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | PDPK1 4179/4885HSD17B10 406/4885MAPT 2667/4885 |
| US-20160340336-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | PDPK1 726/4885HSD17B10 1758/4885MAPT 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.